Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03244735
Other study ID # CCHDiet
Secondary ID
Status Completed
Phase N/A
First received August 5, 2017
Last updated August 10, 2017
Start date January 2017
Est. completion date August 2017

Study information

Verified date August 2017
Source University of Roma La Sapienza
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Atkins diet is a nutritional regimen characterized by ad libitum protein and fat intake, but carbohydrate restriction. It is followed by millions of people around the word as a life-style, but in the last years was proposed as a treatment for the epilepsy, by its capacity to induce the state of ketosis.

Since Authors observed that ketosis could be also useful in migraine, and migraine shares some pathophysiological features with cluster headache, The aim of the study is to test the efficacy of Atkins diet in Cluster Headache by an open label one harm observational study.


Description:

The Atkins diet is a ketogenic high-fat, low-carbohydrate diet for long adopted as lifestyle by people that dislike have an high carbohydrate intake. This nutritional life style seems to account for more energy in the daily activity and an easy weight control. In the last years, researchers showed that a modified Atkins diet (MAD) can be useful to treat drug resistant epilepsy, maybe by the induction of ketogenesis.

Ketogenesis, ketone-body formation, is a physiologic phenomenon also observed in patients following low-carbohydrate high fat diets. Different Authors evidenced a protective effect of ketone bodies also on migraine that shares some pathophysiological features with cluster headache (CH).

CH is the worst form of headache, also called as "suicide headache"; in particular its unremitting form, called Chronic CH (CCH) is regarded as a clinical challenge for neurologist, if refractory to pharmacological treatments. So far, no data are available about a beneficial effect of ketogenesis in CH. However, the beta hydroxybutyrate (BHB) has a chemical formula similar to gamma hydroxybutyrate (GHB) that has shown to be effective in CH. Moreover, ketosis has also a beneficial effect on hypothalamic dysfunctions that are shared by some form of epilepsy and CH.

Aim of this study is verify in an open label observational study if a MAD can be useful in the treatment of CCH. In case of positive outcome, the results could be used as preliminary data to design a double blind versus placebo study, to asses definitively if ketogenesis is really able to prevent/avoid headache attacks in CH.

Methods: By the Italian branch of the Organization for the Understanding of Cluster Headache (OUCH), there will be recruited CCH volunteers that accept to modify their diet according to Atkins Diet for at least three months.

Headache attack frequency will be collected on specific headache-calendars and a comparison between the pre-diet phase and the during-the-diet- phase will be performed.


Recruitment information / eligibility

Status Completed
Enrollment 18
Est. completion date August 2017
Est. primary completion date August 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Diagnosis of CCH (less than 30 consecutive days of attacks remission in the last year)

- kept a headache diary for at least 1 month

- CH onset before the age of 50

Exclusion Criteria:

- over consumption of acute pain-killers (triptan, analgesic, or ergotamine)

- pregnancy or lactation

- type I diabetes

- serious organic or psychiatric disorders that the investigators judged as having the potential to influence the trial evaluation.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Atkins diet
A nutritional regimen characterized by high fat low carbohydrate intake.

Locations

Country Name City State
Italy Policlinico Umberto I Rome

Sponsors (1)

Lead Sponsor Collaborator
University of Roma La Sapienza

Country where clinical trial is conducted

Italy, 

References & Publications (1)

Di Lorenzo C, Coppola G, Sirianni G, Rossi P, Pierelli F. O045. Cluster headache improvement during Ketogenic Diet. J Headache Pain. 2015 Dec;16(Suppl 1):A99. doi: 10.1186/1129-2377-16-S1-A99. Erratum in: J Headache Pain. 2017 Dec;18(1):11. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Attack frequency Reduction of at least 50% of number of attacks per month 3 months
See also
  Status Clinical Trial Phase
Completed NCT02462395 - Anodal Transcranial Direct Stimulation (tDCS) for the Treatment of Chronic Cluster Headache Phase 2/Phase 3
Completed NCT05064397 - A 1-year Trial to Inform About Long-term Exposure to Eptinezumab in Participants With Chronic Cluster Headache (cCH) Phase 3
Recruiting NCT01701245 - Prevention and Acute Treatment of Chronic Cluster Headache Compared to Standard of Care Phase 2
Completed NCT01151631 - Occipital Nerve Stimulation in Medically Intractable Chronic Cluster Headache Phase 3
Recruiting NCT06124534 - Bilateral Occipital Nerve Field Stimulation for the Treatment of dtCCH N/A
Unknown status NCT00399243 - Sumatriptan 4 mg Statdose in the Acute Treatment of Cluster Headache Phase 4
Recruiting NCT05868044 - REsponse to Combined SONS and ONS in Chronic Cluster headachE N/A
Completed NCT01616511 - Pathway CH-1 Long-Term Follow-Up N/A
Completed NCT01359631 - Cephalic Vascular Recording Upon SPG Stimulation N/A
Completed NCT02438826 - A Study of Galcanezumab in Participants With Chronic Cluster Headache Phase 3
Completed NCT02510729 - SPG Neurostimulation in Cluster Patients N/A
Active, not recruiting NCT02168764 - Sphenopalatine Ganglion Stimulation for the Treatment of Chronic Cluster Headache N/A
Completed NCT02797951 - A Study of LY2951742 (Galcanezumab) in Participants With Cluster Headache Phase 3
Not yet recruiting NCT05477459 - LSD to Improve Cluster Headache Impact Trial Phase 2
Terminated NCT02964338 - A Study Comparing the Efficacy and Safety of Fremanezumab (TEV-48125) for the Prevention of Chronic Cluster Headache (CCH) Phase 3
Completed NCT01255813 - Sphenopalatine Ganglion Stimulation for the Acute Treatment of Cluster Headache N/A
Active, not recruiting NCT05023460 - Treatment of Chronic Cluster Headache With TENS and ONS N/A